[A new approach to the evaluation of the effectiveness of antihypertensive therapy in patients with mild and moderate arterial hypertension based on the example of isoptin retard].
Isoptin-retard (Knoll, BASF) in a single dose 240 mg/day provides a significant hypotensive effect in patients with mild and moderate essential hypertension noticeable as early as treatment day 2. Sensitivity to the drug does not tend to decrease with time. The treatment should be conducted under ECG monitoring.